Checked
NU Skin Enterprises, Inc.
NYSE: NUS · Wholesale-Drugs, Proprietaries & Druggists' Sundries · Provo, UT
- Revenue
- $1.49B
- -14.3% vs. prior year
- Net income
- $160.2M
- 10.8% net margin
- Total assets
- $1.41B
- Diluted EPS
- $3.18
Company details
As reported to the SEC
- SEC CIK
- 1021561
- Stock
- NYSE: NUS
- Headquarters
- 75 West Center St, Attn: Gregory Belliston, Provo, UT 84601
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Accelerated filer
- Phone
- (801) 345-1000
- Employer ID (EIN)
- 87-0565309
- Last annual report
- 02/13/2026
- Last quarterly report
- 08/10/2026
Formerly: NU SKIN ENTERPRISES INC (until 09/13/2019); NU SKIN ASIA PACIFIC INC (until 08/13/1998); NU SKIN ASIA INC (until 09/16/1996)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $1.49B | $1.73B | $1.97B | $2.23B | $2.7B |
| Gross profit | $1.03B | $1.18B | $1.36B | $1.59B | $2.02B |
| Operating income | $65.76M | -$151.6M | $48.27M | $110.8M | $234M |
| Net income | $160.2M | -$146.6M | $8.6M | $104.8M | $147.3M |
| Diluted earnings per share | $3.18 | -$2.95 | $0.17 | $2.07 | $2.86 |
| Research and development | $10.8M | $13M | $22.6M | $23.3M | $27.2M |
| Total assets | $1.41B | $1.47B | $1.81B | $1.82B | $1.91B |
| Total liabilities | $600.1M | $817.5M | $986.7M | $923.7M | $993.7M |
| Shareholders' equity | $805.2M | $651.5M | $822M | $897.3M | $912.8M |
| Cash and cash equivalents | $238.6M | $186.9M | $256.1M | $264.7M | $339.6M |
| Long-term debt | $204.2M | $363.6M | $478M | $377.5M | $268.8M |
| Cash from operations | $80.29M | $111.7M | $118.6M | $108.1M | $141.6M |
| Capital expenditures | $34.28M | $41.58M | $58.49M | $59.06M | $68.61M |
Federal and state records filed under the name NU Skin Enterprises, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
FDA recalls
Recalls of food, drugs and devices reported to the FDA
Swipe the table sideways to see more columns.
| Product | Class | Started |
|---|---|---|
| Pharmanex BioGinkgo. Mental Sharpness. 60 Tablets | Class II | 02/13/2017 |
| Pharmanex Cholestin. Cholesterol Health. 60 Softgels. | Class II | 02/13/2017 |
| Pharmanex Cortitrol. Cortisol Management. 60 Capsules | Class II | 02/13/2017 |
Recent filings
137 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
38 insider ownership reports (Forms 3, 4, 5 and 144) were filed about NU Skin Enterprises, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other wholesale-drugs, proprietaries & druggists' sundries
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| McKesson CorpMCK | Irving, TX | $403.4B | $4.76B |
| Cencora, Inc.COR | Conshohocken, PA | $321.3B | $1.55B |
| Cardinal Health IncCAH | Dublin, OH | $254.2B | $1.71B |
| Herbalife Ltd.HLF | George Town, Cayman Islands | $5.04B | $228.3M |
| Cosmos Health Inc.COSM | Thessaloniki, Greece | $65.27M | -$19.14M |
| DataMeds AI, Inc.MEDS | Tampa, FL | $23.34M | -$101.3M |
| Cellyan Biotechnology Co., LtdHKPD | Kowloon, Hong Kong | $20.31M | -$27.06K |
| Stemtech CorpSTEK | Naples, FL | $2.88M | -$4.05M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is NU Skin Enterprises, Inc.'s CIK number?
- NU Skin Enterprises, Inc.'s SEC Central Index Key (CIK) is 1021561.
- What is NU Skin Enterprises, Inc.'s stock ticker?
- NU Skin Enterprises, Inc. trades as NYSE: NUS.
- What was NU Skin Enterprises, Inc.'s revenue?
- NU Skin Enterprises, Inc. reported revenue of $1.49B for the fiscal year ended Dec 31, 2025, -14.3% from the year before.
- When does NU Skin Enterprises, Inc.'s fiscal year end?
- NU Skin Enterprises, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is NU Skin Enterprises, Inc. headquartered?
- NU Skin Enterprises, Inc.'s principal executive office on file with the SEC is in Provo, UT.
- Has NU Skin Enterprises, Inc. had any FDA recalls?
- The FDA lists 3 recalls with NU Skin Enterprises, Inc. as the recalling firm. The latest started Feb 13, 2017.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026